Predictive Models of Treatment Responses and Survival Outcomes in Patients With Osteosarcoma

N/AUnknownNCT05194605

West China Hospital800 enrolled

Overview

The aim of this study was to developed and validated models to predict therapeutic responses and patients' survivals in patients with osteosarcoma and compared these models with currently available models.

The investigator performed a retrospective-prospective cohort study with the aim of developing and validating comprehensive models to predict treatment responses and survival outcomes in patients with biopsy-proven osteosarcoma. Secondly, the investigator aimed to compare the predictive accuracy with currently available noninvasive model.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Osteosarcoma

Interventions

Prediction modelOTHER

We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Receiving no treatment before diagnosis * With written informed consent Exclusion Criteria: * Clinical data missing * Without written informed consent

Locations (1)

West China Hospital, Sichuan University

Chengdu, Sichuan, China

RECRUITING

Outcomes

Primary Outcomes

Treatment response

The primary outcome was the evaluation of treatment response to individualized therapy in patients with osteosarcoma.

Time frame: At least 1-year follow up

Progression-free survival outcomes

The endpoint was defined as the occurrence of progression or recurrence, or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence, or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.

Time frame: At least 5-year follow up

Overall survival outcomes

The endpoint was defined as the occurrence of death or the last follow-up. Patients were followed from the day of histological diagnosis until the occurrence of progression or recurrence or last visit. The outcome was evaluated by an experienced oncologist in each center every 3-6 months. At each visit, a medical history, physical examination, and standard laboratory tests were performed.

Time frame: At least 5-year follow up

Central Contacts

Yuhan Yang, MD

CONTACT

8613258389785 yyh_1023@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.